SLC43A2 and neoplasm: Tumor cells tend to have advantage in glutamine consumption over those immune cells, as tumor cells have over-expressed methionine transporter Slc43a2, thereby restricts methionine metabolism and the antitumor function of T cells.369 However, whether RNA modifications participate in glutamine metabolism of immune cells remains to be explored.